On the stock market since 2011, it operates in the world of health and science. It has 78 employees. Now — the numbers.
This is an established company with proven profits.
The biggest line carries real weight, but it doesn’t decide everything on its own.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
The cash pile is strong; debt and other items pull the grade toward the middle.
Clearly below the class average.
There is growth, but not at top-of-the-class tempo.
The stock has been running stronger than the market lately.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 94% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $79.4M in the vault; even if every debt were paid off, $5.1M would remain.
Over the last 12 months, company executives reported 10 buys and 0 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $5.00 — 46% above today’s price.
Over the last 3 years, sales fell about 6% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 26/100.
The sales tempo runs behind the sector. Council score: 4/10.
On our five-subject report card, FBIO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: FBIO is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (26/100) says the stock isn’t cheap.